These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28700045)

  • 1. Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.
    Pinheiro E; Brum-Soares L; Reis R; Cubides JC
    Rev Soc Bras Med Trop; 2017; 50(3):296-300. PubMed ID: 28700045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to benznidazole for Chagas disease in the United States-Cautious optimism?
    Alpern JD; Lopez-Velez R; Stauffer WM
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005794. PubMed ID: 28910299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
    Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vouching for access.
    Nat Med; 2016 Jul; 22(7):693. PubMed ID: 27387878
    [No Abstract]   [Full Text] [Related]  

  • 5. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America].
    Chaves GC; Abi-Saab Arrieche M; Rode J; Mechali D; Reis PO; Alves RV; Stobbaerts E; Aguilar NG; Ribeiro I
    Rev Panam Salud Publica; 2017 Jun; 41():e45. PubMed ID: 28614468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.
    Alonso-Padilla J; Cortés-Serra N; Pinazo MJ; Bottazzi ME; Abril M; Barreira F; Sosa-Estani S; Hotez PJ; Gascón J
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):145-157. PubMed ID: 30712412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Benzonidazole: one of the rare treatment for Chagas disease].
    Coilliot C; Rouault M; Wolf A; Boulliat C; Beranger C; Gaillard K; Oliver M
    Med Trop (Mars); 2011 Feb; 71(1):25-7. PubMed ID: 21585085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spanish group defeats Shkreli in Chagas voucher race.
    Melton L
    Nat Biotechnol; 2017 Nov; 35(11):1003. PubMed ID: 29121016
    [No Abstract]   [Full Text] [Related]  

  • 11. Access to care for Chagas disease in the United States: a health systems analysis.
    Manne-Goehler J; Reich MR; Wirtz VJ
    Am J Trop Med Hyg; 2015 Jul; 93(1):108-13. PubMed ID: 25986581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition for Chagas disease.
    Burki T
    Lancet Infect Dis; 2019 Jul; 19(7):699. PubMed ID: 31250822
    [No Abstract]   [Full Text] [Related]  

  • 13. Neglect of a Neglected Disease in Italy: The Challenge of Access-to-Care for Chagas Disease in Bergamo Area.
    Repetto EC; Zachariah R; Kumar A; Angheben A; Gobbi F; Anselmi M; Al Rousan A; Torrico C; Ruiz R; Ledezma G; Buoninsegna MC; Khogali M; Van den Bergh R; De Maio G; Egidi AM; Maccagno B; Garelli S
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004103. PubMed ID: 26406325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening.
    Perez-Zetune V; Bialek SR; Montgomery SP; Stillwaggon E
    Am J Trop Med Hyg; 2020 May; 102(5):1086-1089. PubMed ID: 32100696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
    J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Benznidazole and chronic Chagas disease].
    Manigot DA
    Medicina (B Aires); 1984; 44(1):105-6. PubMed ID: 6443011
    [No Abstract]   [Full Text] [Related]  

  • 17. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
    Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of Chagas disease screening in Spain.
    Imaz-Iglesia I; Miguel LG; Ayala-Morillas LE; García-Pérez L; González-Enríquez J; Blasco-Hernández T; Martín-Águeda MB; Sarría-Santamera A
    Acta Trop; 2015 Aug; 148():77-88. PubMed ID: 25917718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should benznidazole be used in chronic Chagas' disease?
    Bestetti RB
    Lancet; 1997 Mar; 349(9052):653. PubMed ID: 9057760
    [No Abstract]   [Full Text] [Related]  

  • 20. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.